SEC Form 4	
------------	--

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

0.5

OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre	1 0		2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [ TNDM	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
ROBERTSON REBECCA B			_ ]	X	Director	10% Owner					
(Last) C/O TANDEM 11075 ROSELI		(Middle) CARE, INC.	3. Date of Earliest Transaction (Month/Day/Year) 11/01/2021		Officer (give title below)	Other (specify below)					
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ndividual or Joint/Group Filing (Check Applicable						
(Street)	CA	92121		X	Form filed by One Re						
·			_		Form filed by More th Person	an One Reporting					
(City)	(State)	(Zip)									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	11/01/2021		<b>M</b> <sup>(1)</sup>		1,108	Α	\$34	1,500	D	
Common Stock	11/01/2021		<b>S</b> <sup>(2)</sup>		1,222	D	\$135.64 <sup>(3)</sup>	278	D	
Common Stock	11/01/2021		<b>S</b> <sup>(2)</sup>		278	D	<b>\$136.35</b> <sup>(4)</sup>	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriva Securi Acquir (A) or Dispos of (D)	Derivative (Month/Day/ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		ate Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$34	11/01/2021		М		1,108		(5)	(6)	Common Stock	1,108	\$34	34,892	D	

Explanation of Responses:

1. Represents shares of common stock received upon exercise of a stock option award.

2. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2021.

3. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$135.05 to \$136.04. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.

4. The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between \$136.19 to \$136.53. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.

5. The option shall vest in 36 equal monthly installments from January 2, 2019, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan")

6. The expiration date for these options is 10 years from the date of grant.

**Remarks:** 

s/ David B. Berger, Attorneyin-Fact for Rebecca B.

Robertson

11/03/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)